Moderna and Merck Cancer Vaccine Trial Keeps Melanoma at Bay, Boosts Market Value by $45 Billion
Product·2 articles across 2 outlets·↩ Updated
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
A late-stage trial of an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. has shown promising results, preventing melanoma from returning in patients. This breakthrough marks a significant advancement in the quest to use vaccines for cancer treatment.
Following the announcement, Moderna's market value surged by $45 billion in a single day, reflecting renewed investor confidence. Analysts are now speculating whether the vaccine's potential impact could rival that of Merck's Keytruda, a leading cancer immunotherapy.
ModernaMerck
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapt”
Bloomberg — Moderna, Merck Cancer Vax Gives Hope“Moderna gained $45 billion in market value in a single day, a surge that b”
biopharma dive — Cancer vaccine win restores Wall Street’s faith in Moderna
AnalysisInterprets it
“After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next”
Yahoo Finance — After Moderna stock surge of 177% on cancer drug breakthrough, here's what Wall Street thinks happens next
SupportCorroborates it
“At an interim data check, investigators of a key trial found the individualize”
biopharma dive — Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
CommentaryOpinion
“As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine be as broad as Keytruda?”
fierce biotech — <a href="/biotech/merck-moderna-cancer-vaccine-data-spur-speculation-keytruda-impact" hreflang="en">Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact</a>
Earlier versions
- Aug 19, 4:58 PM — Moderna Shares Surge 160% on Cancer Vaccine Success, Hitting Short Sellers Hard (5/5)
- Aug 20, 9:04 AM — Moderna Shares Double After Successful Melanoma Vaccine Trial Results (3/3)
- Aug 20, 2:23 PM — Moderna and Merck Shares Soar After mRNA Cancer Vaccine Success in Phase 3 Trial (4/4)
- Aug 20, 2:23 PM — Moderna and Merck Shares Soar After mRNA Cancer Vaccine Success (4/4)
- Aug 20, 3:19 PM — Moderna and Merck Shares Soar After mRNA Cancer Vaccine Success in Phase 3 Trial (3/2)